Please use this identifier to cite or link to this item: https://repositorio.ufrn.br/handle/123456789/25437
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSoares, Bruno Lobão-
dc.contributor.authorOliveira, João Paulo Maia de-
dc.contributor.authorMachado-de-Sousa, João Paulo-
dc.contributor.authorBaker, Glen B.-
dc.contributor.authorDursun, Serdar-
dc.contributor.authorHallak, Jaime E. C.-
dc.date.accessioned2018-06-16T15:43:29Z-
dc.date.available2018-06-16T15:43:29Z-
dc.date.issued2011-09-
dc.identifier.citationSOARES, Bruno Lobão et al.Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Revista Brasileira de Psiquiatria, v. 33, p. 223-224, 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011000300003&lng=en&tlng=en>. Acesso em: 23 mar. 2018.pt_BR
dc.identifier.issn1809-452X-
dc.identifier.urihttps://repositorio.ufrn.br/jspui/handle/123456789/25437-
dc.languageengpt_BR
dc.publisherAssociação Brasileira de Psiquiatriapt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectSchizophreniapt_BR
dc.titleTargeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophreniapt_BR
dc.title.alternativeA via receptor NMDA-óxido nítrico-GMP cíclico como alvo para o desenvolvimento de medicações antipsicóticas não-dopaminérgicas para a esquizofreniapt_BR
dc.typearticlept_BR
dc.identifier.doihttp://dx.doi.org/10.1590/S1516-44462011000300003-
dc.description.resumoSchizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in schizophrenia patients. Recent evidence suggests that dopaminergic abnormalities may be secondary to dysfunctions in multi-neurotransmitter systems modulating dopamine. One of the key neurotransmitters thought to be involved in schizophrenia is glutamate, and there is strong support for the involvement of a hypoactivity of N-methyl-D-aspartate (NMDA) glutamate receptors in the pathogenesis of schizophrenia. However, research with NMDA receptor agonists for the treatment of schizophrenia has produced inconsistent results, which may be due to the development of rapid tolerance to these compounds secondary to down-regulation of NMDA receptors. Perhaps the development of drugs that act on targets downstream NMDA receptors, such as nitric oxide (NO), could avoid the problem of the down-regulation of these receptors.pt_BR
Appears in Collections:CB - DBF - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
TargetingNMDAReceptor_Soares_2011.pdf362,34 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.